BETHLEHEM, Pa., May 8, 2019 /PRNewswire/ -- CryoConcepts,
LP, a market leader in the development and manufacture of
cryosurgical products, announced today they have received FDA
clearance on two new, patent pending, cryosurgical devices for the
physician's office market.
CryoTouch™ is a portable cryosurgical device that delivers
cryogen to lesion sites and can use either applicators or cones
based on the physician's preference. CryoLab® is
a benchtop unit that delivers cryogen for medical practices that
perform a high volume of cryosurgery. The new platforms have
been cleared to treat up to 23 different indications.
"We are excited to get these clearances from the FDA," said
Sam Niedbala, PhD and CEO of
CryoConcepts, LP. "CryoTouch™ and CryoLab® have
been designed to address user needs in a product category that has
not seen innovation in over two decades. Our new, patent
pending, products will deliver greater efficacy and are much
easier-to-use. These new products position CryoConcepts as the only
company that is a one-stop source for cryosurgical products ranging
from disposable devices to capital equipment," he added.
The largest portion of the professional cryosurgical market
consists of two basic product categories – 1. Liquid nitrogen-based
delivery systems used mainly by dermatologists which require
frequent refills due to evaporation and 2. Portable devices such as
the Histofreezer® and Verrucae Freeze®
that are disposable can-like devices used by Pediatricians and
General Practitioners.
"Histofreezer® and Verrucae
Freeze® established the disposable cryosurgical
market in the early 90's," said Bill
Hinchey, CMO of CryoConcepts. "Our new products are
easy-to-use and deliver more effective treatments while being
highly efficient," he added.
The company plans aggressive introductions into a variety of
professional medical markets during 2019. CryoConcepts currently
markets other cryo devices under the CryOmega®,
CryoClear®, and CooLifting® brand
names.
About CryoConcepts, LP
CryoConcepts was founded by Sam
Niedbala, PhD, in 2009 and is located in Bethlehem, PA. Dr. Niedbala was a
co-founder and former Chief Science Officer of OraSure
Technologies, Incorporated (NASDAQ: OSUR) and holds over 50 US and
international patents. The management team also includes
another OraSure co-founder, Bill
Hinchey, who was responsible for the US launch of
Histofreezer in 1991 and spent over a decade in the cryosurgical
business. Mr. Hinchey serves as Chief Marketing Officer of
CryoConcepts. P. Michael
Formica is CryoConcepts' Chief Technology Officer and served
as an Executive Vice President at OraSure Technologies from 2000 to
2016. Mr. Formica was General Manager of the domestic,
international, and OTC Histofreezer business during his tenure at
OraSure.
For more information, please visit
www.CryoConcepts.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryoconcepts-receives-fda-clearance-on-two-cryosurgical-devices-for-the-physician-office-market-300846429.html
SOURCE CryoConcepts, LP